Overview

A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight With Weight Related Comorbidities

Status:
Not yet recruiting

Trial end date:
2025-03-24

Target enrollment:

Participant gender:

Summary

The main purpose of this phase 3b study is to evaluate the efficacy and safety of tirzepatide compared with semaglutide 2.4 milligram (mg) in adult participants who have obesity or overweight with weight related comorbidities without Type 2 Diabetes. The study will last around 78 weeks.

Phase:

Phase 3

Details

Lead Sponsor:

Eli Lilly and Company

Treatments:

Tirzepatide